Whole Genome and Exome Sequencing Markets. By Application, Organism, Product and Whole/Exome with Executive and Consultant Guides. Includes Direct to Consumer Analysis and Impact of Artificial Intelligence. 2025 to 2029

Table of Contents

1. Market Guides

• 1.1. Whole Genome Sequencing Market - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on WGS

2. Introduction and Market Definition

• 2.1. Whole Genome Sequencing Definition In This Report
  • 2.1.1. Whole and Exome Sequencing
  • 2.1.2. Research
  • 2.1.3. Clinical Human
  • 2.1.4. Clinical Human Rapid
  • 2.1.5. Clinical Tumor
  • 2.1.6. Clinical Pathogen
  • 2.1.7. Agri/Other
  • 2.1.8. Direct to Consumer
• 2.2. The Genomics Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics
• 2.6. Sizing the Genome - Not What You Think
  • 2.6.1. Cost, Price and Genome Size, Pricing Practice
• 2.7. GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3. Market Overview

• 3.1. Market Participants Play Different Roles
  • 3.1.1. Instrument Manufacturer
  • 3.1.2. Independent lab specialized/esoteric
  • 3.1.3. Independent lab national/regional
  • 3.1.4. Independent lab analytical
  • 3.1.5. Public National/regional lab
  • 3.1.6. Hospital lab
  • 3.1.7. Physician lab
  • 3.1.8. DTC Lab
  • 3.1.9. Sequencing Labs
  • 3.1.10. Audit body
• 3.2. Whole Genome Sequencing -Markets, Examples and Discussion
  • 3.2.1. Direct to Consumer - Two Approaches
    • 3.2.1.1. The New Age of Medical Information
    • 3.2.1.2. Dangers in DTC-WGS - Health Costs and Regulation
    • 3.2.1.3. Newborn and Prenatal - A Brave New World
    • 3.2.1.4. DTC - How Many Segments?
  • 3.2.2. Research Markets
    • 3.2.2.1. Research Funding and Capital Expense
    • 3.2.2.2. WGS Datasets Preferred
    • 3.2.2.3. Existing research repurposed
    • 3.2.2.4. Organism Wide Market
    • 3.2.2.5. Service Suppliers Respond
  • 3.2.3. Clinical - Understanding Germline and Somatic
    • 3.2.3.1. Somatic - Chasing Mutations and Pharmacogenomics
  • 3.2.4. Pathogen Testing
    • 3.2.4.1. The Hepatitis C Story
    • 3.2.4.2. Will theMicrobiology Department Disappear?
  • 3.2.5. AgriBio - Big Business
    • 3.2.5.1. GMO is Here to Stay
    • 3.2.5.2. WGS Benefits and Risks
    • 3.2.5.3. The New Agriculture
• 3.3. Industry Structure
  • 3.3.1. Hospital's Testing Share
  • 3.3.2. Economies of Scale
  • 3.3.3. Instrument Manufacturer Role
  • 3.3.4. Healthcare Industry Impacts - Still Struggling
    • 3.3.4.1. Can the Healthcare Industry Adapt?
    • 3.3.4.2. Genetic Counselling as an Industry
    • 3.3.4.3. WGES Adoption and Cannibalization
    • 3.3.4.4. The Meaning of Grail

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Diagnostic Factors
  • 4.1.2. Interpreting the Code Otherwise
  • 4.1.3. Changes in Agriculture
  • 4.1.4. Fertility Technology Comes of Age
  • 4.1.5. Pathogen Challenges
• 4.2. Factors Limiting Growth
  • 4.2.1. Increased Competition Lowers Price
  • 4.2.2. Lower Costs
  • 4.2.3. Healthcare Cost Concerns Curtail Growth
  • 4.2.4. Wellness has a downside
  • 4.2.5. GMO Opposition Movement
• 4.3. Sequencing Instrumentation
  • 4.3.1. Instrumentation Tenacity
  • 4.3.2. Declining Cost Changes Industry Structure
  • 4.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
  • 4.3.4. Illumina
  • 4.3.5. ION
  • 4.3.6. Pacific Biosystems
  • 4.3.7. Roche 454
  • 4.3.8. SOLiD
  • 4.3.9. Oxford Nanopore
    • 4.3.9.1. What is Oxford Nanopore Sequencing?
    • 4.3.9.2. What can Oxford Nanopore Sequencingt be used for?
    • 4.3.9.3. Oxford Nanopore Products
  • 4.3.10. Long Reads - Further Segmentation
  • 4.3.11. Linked Reads
  • 4.3.12. Targeted Sequencing Adopts CRISPR
  • 4.3.13. New Sequencing Technologies
    • 4.3.13.1. RNAP sequencing
    • 4.3.13.2. In vitro virus high-throughput sequencing
    • 4.3.13.3. Tunnelling currents DNA sequencing
    • 4.3.13.4. Sequencing by hybridization
    • 4.3.13.5. Sequencing with mass spectrometry
    • 4.3.13.6. Microfluidic Sanger sequencing
    • 4.3.13.7. Microscopy-based techniques

5. WGES Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. GeneDx to Acquire Fabric Genomics
• 5.3. WGS provides faster detection of Salmonella
• 5.4. UltraRapid WGS, Results in 48 Hours
• 5.5. WGS Identifies Desirable Tobacco Genes
• 5.6. The Case for WGS use in All Blood Cancers
• 5.7. $400 Personal WGS
• 5.8. Incorporating WGS into Cancer Care
• 5.9. Epic, GeneDx to broaden WGS potential
• 5.10. Qiagen QiaSeq xHyb Mycobacterium Tuberculosis Panel
• 5.11. WGS Uncovers Genetic causes of cerebral palsy
• 5.12. Rapid WGS Use recommended for Intensive Care
• 5.13. Quest and Ultima Genomics to Develop Tests
• 5.14. WHO launches WGS Guide
• 5.15. Myriad Genetics to Study MRD Testing
• 5.16. Adela Developing Epigenetic Multi-Cancer Detection
• 5.17. Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
• 5.18. Bionano Laboratories Announces New Prenatal Whole Genome Tests
• 5.19. Myriad Genetics Plans Product Launches
• 5.20. Genomics England, Aims to Sequence 100K Newborns
• 5.21. Juno Diagnostics NIPT With At-Home Sample Collection
• 5.22. Cardio Diagnostics Launches Genetic Cardio Risk Test
• 5.23. Universal Genetic Testing in Breast Cancer Further Supported
• 5.24. Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
• 5.25. MyOme Lands Investment for WGS
• 5.26. GenomSys Gains CE Mark for New Genomic Analysis Software
• 5.27. WGS Finds Lung Cancers Fall Into Molecular Subtypes
• 5.28. Testing Distinguishes Benign Tumors From Precancerous Condition
• 5.29. Plan to Sequence All Newborns in UK
• 5.30. Clear Labs Raises $60M for Nanopore Sequencing
• 5.31. Variantyx Expands Into Prenatal, Cancer Testing
• 5.32. Whole-Genome Sequencing Aids Diagnosis in Stockholm
• 5.33. Variantyx Raises $20M
• 5.34. Nonacus WGS Service for SARS-CoV-2 Laboratories
• 5.35. Center to Report Risk Scores in Clinical WGS
• 5.36. Stanford Launches WGS for Cardiovascular Testing
• 5.37. Illumina and NY Healthcare Partner on Clinical WGS
• 5.38. Increased Adoption of WGS Needs Acceptance by Payors, Providers
• 5.39. Veritas Intercontinental Completes Euro-5M Series B Financing Round
• 5.40. M2GEN and Discovery Life Sciences in Bioinformatics Agreement
• 5.41. Genomics England Adopts Quantum ActiveScale Object Storage
• 5.42. GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
• 5.43. NHS Wales Introduces WGS for Critically Ill Newborns
• 5.44. Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
• 5.45. C2i Genomics to Launch Trials for MRD Detection Tech
• 5.46. Roche Acquires Sequencing Company Stratos Genomics
• 5.47. UK COVID-19 Sequencing Consortium Launches
• 5.48. Invitae Acquires Three Companies: YouScript, Genelex, Diploid
• 5.49. Experience From Centralized Genomic Medicine Lab
• 5.50. MGI to Enable $100 Human Genome
• 5.51. Nebula Genomics offers $299 WGS
• 5.52. Team to Study Campylobacter Omics
• 5.53. Veritas Genetics Restarts US Business
• 5.54. NEOGEN, Gencove partner to advance animal genomics

6. Profiles of Key Companies

• 6.1. 10x Genomics, Inc.
• 6.2. 1928 Diagnostics
• 6.3. 23andME Inc.
• 6.4. Abbott Laboratories
• 6.5. AccuraGen Inc.
• 6.6. Adaptive Biotechnologies
• 6.7. Admera Health, LLC
• 6.8. Agilent/Dako
• 6.9. Akonni Biosystems
• 6.10. Amoy Diagnostics Co., Ltd.
• 6.11. Ancestry.com LLC
• 6.12. Anchor Dx
• 6.13. ARUP Laboratories
• 6.14. BaseClear
• 6.15. Baylor Miraca Genetics Laboratories
• 6.16. Beckman Coulter Diagnostics
• 6.17. Becton, Dickinson and Company
• 6.18. BGI Genomics Co. Ltd
• 6.19. Bioarray Genetics
• 6.20. Biocept, Inc.
• 6.21. Biodesix Inc.
• 6.22. BioFluidica
• 6.23. BioGenex
• 6.24. Biolidics Ltd
• 6.25. bioMerieux Diagnostics
• 6.26. Bioneer Corporation
• 6.27. Bio-Rad Laboratories, Inc
• 6.28. Bio-Techne
• 6.29. C2i Genomics
• 6.30. Caris Molecular Diagnostics
• 6.31. CellMax Life
• 6.32. Centogene
• 6.33. Circulogene
• 6.34. Clear Labs
• 6.35. Clinical Genomics
• 6.36. Complete Genomics, Inc. - A BGI Company
• 6.37. CosmosID
• 6.38. Dante Labs
• 6.39. Datar Cancer Genetics Limited
• 6.40. Day Zero Diagnostics.
• 6.41. Diasorin S.p.A.
• 6.42. Element Biosciences
• 6.43. Element Biosciences
• 6.44. Epic Sciences
• 6.45. Epigenomics AG
• 6.46. Eurofins Scientific
• 6.47. Excellerate Bioscience
• 6.48. Fabric Genomics
• 6.49. Freenome
• 6.50. FUJIFILM Wako Diagnostics
• 6.51. Fulgent Genetics
• 6.52. GE Global Research
• 6.53. Gencove
• 6.54. Genedrive
• 6.55. GeneDx Holdings
• 6.56. GeneFirst Ltd.
• 6.57. Genetron Holdings
• 6.58. Genewiz
• 6.59. Genomics England
• 6.60. Genomics Personalized Health (GPH)
• 6.61. GenomOncology
• 6.62. Genzyme Corporation
• 6.63. Grifols
• 6.64. Guardant Health
• 6.65. Guardiome
• 6.66. HeiScreen
• 6.67. Helix
• 6.68. Helix OpCo
• 6.69. Helomics
• 6.70. Hologic
• 6.71. HTG Molecular Diagnostics
• 6.72. Human Longevity, Inc.
• 6.73. iCellate
• 6.74. Illumina
• 6.75. Incell Dx
• 6.76. Inivata
• 6.77. Invitae Corporation
• 6.78. Invivoscribe
• 6.79. Karius
• 6.80. Lunglife AI Inc
• 6.81. Macrogen
• 6.82. MDNA Life SCIENCES, Inc.
• 6.83. MDx Health
• 6.84. Medgenome
• 6.85. Meridian Bioscience
• 6.86. Mesa Biotech (Thermo Fisher)
• 6.87. Mesa Laboratories, Inc.
• 6.88. miR Scientific
• 6.89. MNG Labs
• 6.90. NantHealth, Inc.
• 6.91. Natera
• 6.92. Nebula Genomics
• 6.93. NeoGenomics
• 6.94. New England Biolabs, Inc.
• 6.95. Novogene Bioinformatics Technology Co., Ltd.
• 6.96. Omega Bioservices
• 6.97. Oncocyte
• 6.98. OncoDNA
• 6.99. OpGen
• 6.100. ORIG3N, Inc.
• 6.101. Origene Technologies
• 6.102. Oxford Nanopore Technologies
• 6.103. Pacific Biosciences
• 6.104. Panagene
• 6.105. Pathogenomix
• 6.106. PathoQuest S.A.
• 6.107. Personal Genome Diagnostics
• 6.108. Personalis
• 6.109. Precipio
• 6.110. PrecisionMed
• 6.111. Promega
• 6.112. Protagen Diagnostics
• 6.113. Qiagen
• 6.114. QuantuMDx
• 6.115. Regeneron Pharmaceuticals
• 6.116. Revvity
• 6.117. Roche Molecular Diagnostics
• 6.118. Roswell Biotechnologies
• 6.119. Seegene
• 6.120. Sequencing.com
• 6.121. Siemens Healthineers
• 6.122. simfo GmbH
• 6.123. Singlera Genomics Inc.
• 6.124. Singular Genomics
• 6.125. SkylineDx
• 6.126. Standard BioTools
• 6.127. Sure Genomics, Inc.
• 6.128. Sysmex
• 6.129. Sysmex Inostics
• 6.130. Tempus Labs, Inc.
• 6.131. Thermo Fisher Scientific Inc.
• 6.132. Ultima Genomics
• 6.133. Ultima Genomics
• 6.134. Variantyx
• 6.135. Volition
• 6.136. Vyant Bio
• 6.137. Zymo Research Corp

7. The Global Market for Whole Genome Sequencing

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Application - Overview
  • 7.2.1. Table - Global Market by Application
  • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Application - Base Year
  • 7.2.4. Chart - Global Market by Application - Final Year
  • 7.2.5. Chart - Global Market by Application - Share by Year
  • 7.2.6. Chart - Global Market by Application - Segment Growth
• 7.3. Global Market by Organism - Overview
  • 7.3.1. Table - Global Market by Organism
  • 7.3.2. Chart - Global Market by Organism - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Organism - Base Year
  • 7.3.4. Chart - Global Market by Organism - Final Year
  • 7.3.5. Chart - Global Market by Organism - Share by Year
  • 7.3.6. Chart - Global Market by Organism - Segment Growth
• 7.4. Global Market by Product - Overview
  • 7.4.1. Table - Global Market by Product
  • 7.4.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Product - Base Year
  • 7.4.4. Chart - Global Market by Product - Final Year
  • 7.4.5. Chart - Global Market by Product - Share by Year
  • 7.4.6. Chart - Global Market by Product - Segment Growth
• 7.5. Global Market by Whole/Exome - Overview
  • 7.5.1. Table - Global Market by Whole/Exome
  • 7.5.2. Chart - Global Market by Whole/Exome - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market by Whole/Exome - Base Year
  • 7.5.4. Chart - Global Market by Whole/Exome - Final Year
  • 7.5.5. Chart - Global Market by Whole/Exome - Share by Year
  • 7.5.6. Chart - Global Market by Whole/Exome - Segment Growth

8. Global Whole Genome Sequencing Markets - by Application

• 8.1. Research
  • 8.1.1. Table Research - by Country
  • 8.1.2. Chart - Research Growth
• 8.2. Clinical Human
  • 8.2.1. Table Clinical Human - by Country
  • 8.2.2. Chart - Clinical Human Growth
• 8.3. Clinical Human Rapid
  • 8.3.1. Table Clinical Human Rapid - by Country
  • 8.3.2. Chart - Clinical Human Rapid Growth
• 8.4. Clinical Tumor
  • 8.4.1. Table Clinical Tumor - by Country
  • 8.4.2. Chart - Clinical Tumor Growth
• 8.5. Clinical Pathogen
  • 8.5.1. Table Clinical Pathogen - by Country
  • 8.5.2. Chart - Clinical Pathogen Growth
• 8.6. Direct to Consumer
  • 8.6.1. Table Direct to Consumer - by Country
  • 8.6.2. Chart - Direct to Consumer Growth
• 8.7. Agriculture/Other
  • 8.7.1. Table Agriculture/Other - by Country
  • 8.7.2. Chart - Agriculture/Other Growth

9. Global Whole Genome Sequencing Markets - by Organism

• 9.1. Human
  • 9.1.1. Table Human - by Country
  • 9.1.2. Chart - Human Growth
• 9.2. Pathogen
  • 9.2.1. Table Pathogen - by Country
  • 9.2.2. Chart - Pathogen Growth
• 9.3. Other Organism
  • 9.3.1. Table Other Organism - by Country
  • 9.3.2. Chart - Other Organism Growth

10. Global Whole Genome Sequencing Markets - by Product

• 10.1. Instruments
  • 10.1.1. Table Instruments - by Country
  • 10.1.2. Chart - Instruments Growth
• 10.2. Reagents
  • 10.2.1. Table Reagents - by Country
  • 10.2.2. Chart - Reagent Growth
• 10.3. Analysis
  • 10.3.1. Table Analysis - by Country
  • 10.3.2. Chart - Analysis Growth
• 10.4. Software & Other
  • 10.4.1. Table Software & Other - by Country
  • 10.4.2. Chart - Software & Other Growth

11. Global Whole Genome Sequencing Markets - by Whole/Exome

• 11.1. Whole Genome
  • 11.1.1. Table Whole Genome - by Country
  • 11.1.2. Chart - Whole Genome Growth
• 11.2. Exome Only
  • 11.2.1. Table Exome Only - by Country
  • 11.2.2. Chart - Exome Only Growth
• 11.3. Other/Mix
  • 11.3.1. Table Other/Mix - by Country
  • 11.3.2. Chart - Other/Mix Growth

12. Vision of the Future of Whole Genome Sequencing

13. Appendices

• 13.1. United States Medicare System: Laboratory Fees Schedule
• 13.2. The Most Used IVD Assays
• 13.3. The Highest Grossing Assays
• 13.4. The Whole Genome Sequence of SARS-CoV-2

Table of Tables

• Table 1: The Base Pairs
• Table 2: Most Common Traditional Genetic Disorders
• Table 3: List of GLOBAL SEQUENCING LOCATIONS
• Table 4: Market Players by Type
• Table 5: The Different Markets for Whole Genome Sequencing
• Table 6: DTC Sub Segments
• Table 7: Roles of WGS in AgriBio
• Table 8: The Factors Driving Growth
• Table 9: Factors Limiting Growth
• Table 10: Listing of Current NGS Instrument Specifications
• Table 11: Six New Sequencing Technologies
• Table 12: Global Market by Region
• Table 13: Global Market by Application
• Table 14: Global Market by Organism
• Table 15: Global Market by Product
• Table 16: Global Market by Whole/Exome
• Table 17: Research by Country
• Table 18: Clinical Human by Country
• Table 19: Clinical Human Rapid by Country
• Table 20: Clinical Tumor by Country
• Table 21: Clinical Pathogen by Country
• Table 22: Direct to Consumer by Country
• Table 23: Agriculture/Other by Country
• Table 24: Human by Country
• Table 25: Pathogen by Country
• Table 26: Other Organism by Country
• Table 27: Instruments by Country
• Table 28: Reagents by Country
• Table 29: Analysis by Country
• Table 30: Software & Other by Country
• Table 31: Whole Genome by Country
• Table 32: Exome Only by Country
• Table 33: Other/Mix by Country
• Table 34: Clinical Lab Fee Schedule
• Table 35: The Most Common Assays
• Table 36: Largest Revenue Assays

Table of Figures

• Figure 1: Global Healthcare Spending
• Figure 2: The Lab Test Pie
• Figure 3: Size of Genome for Various Species
• Figure 4: Cost To Sequence a Human Genome
• Figure 5: Base Year Country Market Share Chart
• Figure 6: Global Market by Application - Base vs. Final Year
• Figure 7: Global Market by Application Base Year
• Figure 8: Global Market by Application Final Year
• Figure 9: Application Type Share by Year
• Figure 10: by Application Segment Growth
• Figure 11: by Organism - Base vs. Final Year
• Figure 12: by Organism Market Base Year
• Figure 13: by Organism Market Final Year
• Figure 14: by Organism Share by Year
• Figure 15: by Organism Segment Growth
• Figure 16: by Product - Base vs. Final Year
• Figure 17: by Product Market Base Year
• Figure 18: by Product Market Final Year
• Figure 19: by Product Share by Year
• Figure 20: by Product Segment Growth
• Figure 21: by Whole/Exome - Base vs. Final Year
• Figure 22: by Whole/Exome Market Base Year
• Figure 23: by Whole/Exome Market Final Year
• Figure 24: by Whole/Exome Share by Year
• Figure 25: by Whole/Exome Segment Growth
• Figure 26: Research Growth
• Figure 27: Clinical Human Growth
• Figure 28: Clinical Human Growth
• Figure 29: Clinical Tumor Growth
• Figure 30: Clinical Pathogen Growth
• Figure 31: Direct to Consumer Growth
• Figure 32: Agriculture/Other Growth
• Figure 33: Human Growth
• Figure 34: Pathogen Growth
• Figure 35: Other Organism Growth
• Figure 36: Instruments Growth
• Figure 37: Reagent Growth
• Figure 38: Analysis Growth
• Figure 39: Software & Other Growth
• Figure 40: Whole Genome Growth
• Figure 41: Exome Only Growth
• Figure 42: Other/Mix Growth